Inhibiting STAT3 can reduce noradrenaline-induced expression of NGF, matrix metallopeptidase (MMP) 2, and MMP 9, as well as diminish the migratory and invasive capabilities of pancreatic cancer cells. Here, STAT3 is linked to pancreatic neoplasm.